AB40465

Anti-LAG-3 antibody [11E3]

Name: Anti-LAG-3 antibody [11E3] (ab40465) | Abcam
Brand: Abcam Limited
SKU: AB40465
Price: 605 USD
Availability: InStock
Rating: 4 (2 reviews)

(2 Reviews)

(10 Publications)

Mouse Monoclonal LAG-3 antibody. Suitable for IP, BL, Flow Cyt, ELISA, WB, IHC-P, ICC/IF, IHC-Fr and reacts with Monkey, Human samples. Cited in 10 publications. Immunogen corresponding to Recombinant Full Length Protein corresponding to Human LAG3.

View Alternative Names

CD223, FDC, LAG3, Lymphocyte activation gene 3 protein, LAG-3

1 Images

Flow Cytometry - Anti-LAG-3 antibody [11E3] (AB40465)

Flow Cyt

Unknown

Flow Cytometry - Anti-LAG-3 antibody [11E3] (AB40465)

Overlay histogram showing Jurkat cells stained with ab40465 (red line). The cells were fixed with 80% methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab40465, 1μg/1x10⁶ cells) for 30 min at 22°C. The secondary antibody used was Alexa Fluor^® 488 goat anti-mouse IgG (H&L) (ab150113) at 1/2000 dilution for 30 min at 22°C. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 1μg/1x10⁶ cells) used under the same conditions. Unlabelled sample (blue line) was also used as a control. Acquisition of >5,000 events were collected using a 20mW Argon ion laser (488nm) and 525/30 bandpass filter.

Key facts

Host species

Mouse

Clonality

Monoclonal

Clone number

11E3

Isotype

IgG1

Carrier free

Reacts with

Human, Monkey

Applications

BL, ICC/IF, Flow Cyt, IHC-Fr, IHC-P, WB, IP, ELISA

applications

Immunogen

Recombinant Full Length Protein corresponding to Human LAG3.

P18627

Specificity

Recognizes the first N-terminal D1 domain of LAG-3.

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "BL" : {"fullname" : "Blocking", "shortname":"BL"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"}, "ELISA" : {"fullname" : "ELISA", "shortname":"ELISA"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "IHCFr" : {"fullname" : "Immunohistochemistry (Frozen sections)", "shortname":"IHC-Fr"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IP-species-checked": "guaranteed", "IP-species-dilution-info": "", "IP-species-notes": "", "BL-species-checked": "guaranteed", "BL-species-dilution-info": "", "BL-species-notes": "", "FlowCyt-species-checked": "testedAndGuaranteed", "FlowCyt-species-dilution-info": "1 µg for 10^6 Cells", "FlowCyt-species-notes": "", "ELISA-species-checked": "guaranteed", "ELISA-species-dilution-info": "", "ELISA-species-notes": "", "WB-species-checked": "guaranteed", "WB-species-dilution-info": "", "WB-species-notes": "", "IHCP-species-checked": "guaranteed", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "ICCIF-species-checked": "guaranteed", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "IHCFr-species-checked": "guaranteed", "IHCFr-species-dilution-info": "", "IHCFr-species-notes": "" }, "Monkey": { "IP-species-checked": "guaranteed", "IP-species-dilution-info": "", "IP-species-notes": "", "BL-species-checked": "guaranteed", "BL-species-dilution-info": "", "BL-species-notes": "", "FlowCyt-species-checked": "predicted", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "", "ELISA-species-checked": "guaranteed", "ELISA-species-dilution-info": "", "ELISA-species-notes": "", "WB-species-checked": "guaranteed", "WB-species-dilution-info": "", "WB-species-notes": "", "IHCP-species-checked": "guaranteed", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "ICCIF-species-checked": "guaranteed", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "IHCFr-species-checked": "guaranteed", "IHCFr-species-dilution-info": "", "IHCFr-species-notes": "" } } }

style

left-column

style

left-column

Properties and storage information

Form

Liquid

Purification technique

Affinity purification Protein A

Purification notes

Purified from concentrated hybridoma tissue culture supernatant by Protein A Sepharose CL-4B Flow Fast Column. Purity >95% (SDS-PAGE).

Storage buffer

Preservative: 0.02% Sodium azide Constituents: PBS, 10% Glycerol (glycerin, glycerine)

Shipped at conditions

Blue Ice

Appropriate short-term storage duration

1-2 weeks

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

-20°C

Aliquoting information

Upon delivery aliquot

Storage information

Avoid freeze / thaw cycle

style

left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

LAG-3 also known as CD223 is a transmembrane protein with a mass of approximately 70 kDa. It acts as a checkpoint molecule similar to CTLA-4 and PD-1 in the immune system. LAG-3 is expressed on activated T cells natural killer cells and some dendritic cells. It interacts with its ligand MHC class II leading to inhibition of cellular proliferation and cytokine secretion an important part of immune response regulation.

Biological function summary

LAG-3 is involved in maintaining immune homeostasis and preventing autoimmunity. It is not part of a complex but works in synergy with other immune checkpoint molecules. When interacting with MHC class II LAG-3 transmits inhibitory signals that attenuate immune cell responses. Its role in immune regulation helps to balance immune activation and tolerance which is essential for preventing tissue damage while protecting against pathogens.

Pathways

The inhibitory role of LAG-3 integrates into the T cell receptor (TCR) signaling pathway and is also linked to the PD-1 signaling pathway. In TCR signaling LAG-3 negatively regulates T cell activation. LAG-3 is functionally related to proteins like PD-1 and CTLA-4 sharing similar roles in immune checkpoint pathways that are critical for maintaining immune balance.

LAG-3 has links to cancer and autoimmune diseases. In cancer LAG-3 expression on tumor-infiltrating lymphocytes correlates with immune evasion by tumors. This relationship appears in various cancers including melanoma and renal cell carcinoma. In autoimmune diseases LAG-3's expression on regulatory T cells helps control conditions such as multiple sclerosis. It collaborates with CTLA-4 in modulating immune responses that prevent excessive immune activation and tissue damage associated with autoimmunity.

style

left-column

style

left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

Target data

Lymphocyte activation gene 3 protein : Inhibitory receptor on antigen activated T-cells (PubMed : 20421648, PubMed : 7805750, PubMed : 8647185). Delivers inhibitory signals upon binding to ligands, such as FGL1 (By similarity). FGL1 constitutes a major ligand of LAG3 and is responsible for LAG3 T-cell inhibitory function (By similarity). Following TCR engagement, LAG3 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation (By similarity). May inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1, possibly by acting as a coreceptor for PDCD1/PD-1 (By similarity). Negatively regulates the proliferation, activation, effector function and homeostasis of both CD8(+) and CD4(+) T-cells (PubMed : 20421648, PubMed : 7805750, PubMed : 8647185). Also mediates immune tolerance : constitutively expressed on a subset of regulatory T-cells (Tregs) and contributes to their suppressive function (By similarity). Also acts as a negative regulator of plasmacytoid dendritic cell (pDCs) activation (By similarity). Binds MHC class II (MHC-II); the precise role of MHC-II-binding is however unclear (PubMed : 8647185).. Secreted lymphocyte activation gene 3 protein. May function as a ligand for MHC class II (MHC-II) on antigen-presenting cells (APC), promoting APC activation/maturation and driving Th1 immune response.

See full target information LAG3

style

left-column

Publications (10)

Recent publications for all applications. Explore the full list and refine your search

Molecular medicine (Cambridge, Mass.) 31:298 PubMed41023624

2025

LAG-3 palmitoylation-inducing dysfunction of decidual CD4T cells is associated with recurrent pregnancy loss.

Applications

Unspecified application

Species

Unspecified reactive species

Liyuan Cui,Fengrun Sun,Xinhang Meng,Yujie Luo,Jinfeng Qian,Songcun Wang

Frontiers in pharmacology 16:1611637 PubMed40693271

2025

Antagonizing IL-6 receptor restores pancreatic tissue resident NK cells activation and ameliorates pancreatic injury in the mouse model of MASH.

Applications

Unspecified application

Species

Unspecified reactive species

Johnny Amer,Diana Abu Arra,Ahmad Salhab,Faris Kayed,Muneer Maali,Raghad Shweiki,Mustafa Ghanim

OncoTargets and therapy 13:9785-9795 PubMed33061457

2020

MiRNA505/NET1 Axis Acts as a CD8 T-TIL Regulator in Non-Small Cell Lung Cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Pengyuan Zhu,Zhenchuan Liu,Haitao Huang,Chongjun Zhong,Yongxin Zhou

Leukemia research reports 14:100215 PubMed32695574

2020

Immune checkpoints bone marrow expression as the predictor of clinical outcome in myelodysplastic syndrome.

Applications

Unspecified application

Species

Unspecified reactive species

Nikolai Tcvetkov,Artem Gusak,Elena Morozova,Ivan Moiseev,Vadim Baykov,Maria Barabanshikova,Kirill Lepik,Evgenyi Bakin,Julia Vlasova,Anna Osipova,Ludmila Zubarovskaya,Boris Afanasyev

Journal of clinical laboratory analysis 34:e23244 PubMed32077528

2020

Ectopic expression of LAG-3 in non-small-cell lung cancer cells and its clinical significance.

Applications

Unspecified application

Species

Unspecified reactive species

Chenglong Ma,Xiao Sun,Dong Shen,Yuejun Sun,Naifu Guan,Chunjian Qi

Annals of translational medicine 7:776 PubMed32042792

2020

Characterization of LAG-3, CTLA-4, and CD8 TIL density and their joint influence on the prognosis of patients with esophageal squamous cell carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Wenjia Wang,Donglai Chen,Yuhuan Zhao,Ting Zhao,Junmiao Wen,Yiming Mao,Chang Chen,Yonghua Sang,Yongsheng Zhang,Yongbing Chen

Journal of immunotherapy (Hagerstown, Md. : 1997) 42:279-283 PubMed31219974

2019

LAG3 in Solid Tumors as a Potential Novel Immunotherapy Target.

Applications

Unspecified application

Species

Unspecified reactive species

Su Jin Lee,Sun-Ju Byeon,Jeeyun Lee,Se Hoon Park,Joon Oh Park,Young Suk Park,Won Ki Kang,Ho Yeong Lim,Kyoung-Mee Kim,Seung Tae Kim

Journal of the American Academy of Dermatology 81:219-227 PubMed30880064

2019

Expression of lymphocyte-activating gene 3 and T-cell immunoreceptor with immunoglobulin and ITIM domains in cutaneous melanoma and their correlation with programmed cell death 1 expression in tumor-infiltrating lymphocytes.

Applications

Unspecified application

Species

Unspecified reactive species

Woo Jin Lee,Ye Jin Lee,Myoung Eun Choi,Kyung A Yun,Chong Hyun Won,Mi Woo Lee,Jee Ho Choi,Sung Eun Chang

Journal of translational medicine 16:86 PubMed29615076

2018

Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer.

Applications

IHC-P

Species

Human

Koji Takada,Shinichiro Kashiwagi,Wataru Goto,Yuka Asano,Katsuyuki Takahashi,Tsutomu Takashima,Shuhei Tomita,Masahiko Ohsawa,Kosei Hirakawa,Masaichi Ohira

Proceedings of the National Academy of Sciences of the United States of America 94:5744-9 PubMed9159144

1997

Characterization of the major histocompatibility complex class II binding site on LAG-3 protein.

Applications

Unspecified application

Species

Unspecified reactive species

B Huard,R Mastrangeli,P Prigent,D Bruniquel,S Donini,N El-Tayar,B Maigret,M Dréano,F Triebel

View all publications

style

left-column

style

left-column

style

right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.

For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Anti-LAG-3 antibody [11E3]

Flow Cytometry - Anti-LAG-3 antibody [11E3] (AB40465)

Key facts

Host species

Clonality

Clone number

Isotype

Carrier free

Reacts with

Applications

Immunogen

Specificity

Reactivity data

Properties and storage information

Form

Purification technique

Purification notes

Storage buffer

Shipped at conditions

Appropriate short-term storage duration

Appropriate short-term storage conditions

Appropriate long-term storage conditions

Aliquoting information

Storage information

Supplementary information

Biological function summary

Pathways

Product protocols

Target data

Publications (10)

Alternative Products

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Complementary Products

Assay Kits

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Product promise